Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Arcadia Biosciences's Sloan Ratio for the quarter that ended in Sep. 2024 was 5.62%.
Warning Sign:
When sloan ratio (28.71)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Sep. 2024, Arcadia Biosciences has a Sloan Ratio of 5.62%, indicating the company is in the safe zone and there is no funny business with accruals.
Arcadia Biosciences Sloan Ratio % Historical Data
The historical data trend for Arcadia Biosciences's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Arcadia Biosciences's Sloan Ratio %
For the Packaged Foods subindustry, Arcadia Biosciences's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcadia Biosciences's Sloan Ratio % Distribution in the Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Arcadia Biosciences's Sloan Ratio % falls into.
Arcadia Biosciences Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Arcadia Biosciences's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Arcadia Biosciences's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was -2.853 (Dec. 2023 ) + -2.423 (Mar. 2024 ) + 1.061 (Jun. 2024 ) + -1.612 (Sep. 2024 ) = $-5.83 Mil.
Arcadia Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was -4.145 (Dec. 2023 ) + -3.21 (Mar. 2024 ) + -2.456 (Jun. 2024 ) + -1.752 (Sep. 2024 ) = $-11.56 Mil.
Arcadia Biosciences's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was 0.052 (Dec. 2023 ) + 0.004 (Mar. 2024 ) + 4.643 (Jun. 2024 ) + 0.18 (Sep. 2024 ) = $4.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcadia Biosciences (NAS:RKDA) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Sep. 2024, Arcadia Biosciences has a Sloan Ratio of 5.62%, indicating the company is in the safe zone and there is no funny business with accruals.
Arcadia Biosciences Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Arcadia Biosciences's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RKDA has been successfully added to your 